BOI

FR0000061129

Pharmaceuticals

Real-time Euronext Paris Other stock markets 13:27:51 16/07/2024 BST			5-day change	1st Jan Change
31.7 ^EUR	+0.48%		0.00%	-21.18%

07-04	Boiron: changes in governance	CF
04-25	Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Boiron : ACTIVITY IN 2016

January 26, 2017 at 05:35 pm

(Unaudited data)

CUMULATIVE ACTIVITY AS OF THE END OF DECEMBER 2016

thousands of euros	2015	2016	Variation at current exchange rates	Variation at constant exchange rates
France	361,765	370,870	+2.5%	+2.5%
Europe (excluding France)	167,714	163,849	-2.3%	-0.3%
North America	63,858	64,916	+1.7%	+1.9%
Other countries	14,466	14,854	+2.7%	+3.7%
Group total	607,803	614,489	+1.1%	+1.7%

thousands of euros	2015	2016	Variation at current exchange rates	Variation at constant exchange rates
Non-proprietary Homeopathic Medicines	310,555	313,365	+0.9%	+0.9%
OTC Specialties	296,954	299,672	+0.9%	+2.1%
Other	294	1,452	+393.9%	+393.9%
Group total	607,803	614,489	+1.1%	+1.7%

QUARTERLY ACTIVITY IN 2016 (variation at current exchange rate)

thousands of euros

1^st quarter

2^nd quarter

3^rdquarter

4^th quarter

2015

2016

Var.
16/15

2015

2016

Var. 16/15

2015

2016

Var.
16/15

2015

2016

Var.
16/15

France

89,584

90,494

+1.0%

76,864

80,469

+4.7%

97,767

98,840

+1.1%

97,550

101,067

+3.6%

Europe (excluding France)

40,657

43,685

+7.4%

29,943

31,572

+5.4%

50,614

41,273

-18.5%

46,500

47,319

+1.8%

North America

17,193

16,064

-6.6%

12,894

14,113

+9.5%

16,055

16,020

-0.2%

17,716

18,719

+5.7%

Other countries

4,622

3,846

-16.8%

3,816

4,061

+6.4%

3,594

3,280

-8.7%

2,434

3,667

+50.7%

Group total

152,056

154,089

+1.3%

123,517

130,215

+5.4%

168,030

159,413

-5.1%

164,200

170,772

+4.0%

thousands of euros

1^st quarter

2^nd quarter

3^rd quarter

4^th quarter

2015

2016

Var.
16/15

2015

2016

Var.
16/15

2015

2016

Var.
16/15

2015

2016

Var.
16/15

Non-proprietary Homeopathic Medicines

79,191

80,147

+1.2%

74,354

76,001

+2.2%

73,677

73,913

+0.3%

83,333

83,304

-0.0%

OTC Specialties

72,880

73,743

+1.2%

49,030

53,719

+9.6%

94,328

85,319

-9.6%

80,716

86,891

+7.7%

Other

-15

199

133

495

+272.2%

181

+624.0%

151

577

+282.1%

Group total

152,056

154,089

+1.3%

123,517

130,215

+5.4%

168,030

159,413

-5.1%

164,200

170,772

+4.0%

HIGHLIGHTS OF THE FOURTH QUARTER

Sales revenue in the fourth quarter 2016 grew by 4% (+3.7% at constant rate). This growth is linked to the context of flu pathology at the end of the year.

Annual sales revenue amounted €614,489 thousand, in increase by 1.1% against 2015 (+1.7% at constant rate). Thus, the 2016 operating income will be slightly higher than in 2015.

On December 14, 2016, a project of new organization of the establishments in France has been presented to the Central Works Committee. The consultation with the social partners will continue until March 2017.

Our next update: March 15, 2017, after the close of the stock market, publication of 2016 results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com

Regulated information
News releases under ongoing reporting obligations:
- Information on annual revenues
- News releases under ongoing reporting obligations

Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-47163-cp-boiron-260117.pdf

Latest news about BOIRON

Boiron: changes in governance	07-04	CF
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Boiron: nearly 600,000 shares tendered to the OPAS	02-02	CF
Boiron: OPAS open from January 11 to 31	01-11	CF
Boiron: Orfim crosses the 5% threshold	13/10/23	CF
Boiron: agreement to sell majority stake signed	05/10/23	CF
Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2023	10/09/23	CI
Boiron: share price up, analyst raises target	07/09/23	CF
Oddo BHF Raises Boiron PT, Maintains Outperform Rating	07/09/23	MT
BOIRON : Oddo BHF raises its target price on the stock	07/09/23	CF
Boiron: 23% rise in half-year net income	07/09/23	CF
Boiron: sales down by almost 7% in 1st half-year	19/07/23	CF
Boiron: family shareholders to launch takeover bid	04/07/23	CF
Boiron: listing suspended prior to announcement	04/07/23	CF
Boiron SAÂ Board intends to launch an Equity Buyback onÂ July 4, 2023.	04/07/23	CI
Boiron: in the green after its quarterly sales figures	28/04/23	CF
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2022	22/03/23	CI
Boiron: 56.4% increase in net income by 2022	21/03/23	CF
Boiron SA Recommends Dividend, Payable on June 3, 2023	20/03/23	CI
CAC40: day in green, week in red, close to 7000pts	20/01/23	CF
CAC40: back above 7,000, despite sharp rise in interest rates	20/01/23	CF
CAC40: flirts with 7,000, gap with US indices widens	20/01/23	CF
CAC40: back on the right foot after yesterday's plunge	20/01/23	CF
Boiron: 17% growth in annual sales	20/01/23	CF
Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2022	15/09/22	CI

Chart BOIRON

Duration

Period

More charts

Company Profile

Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues. Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin. There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties). BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries. Net sales are distributed geographically as follows: France (47.9%), Europe (24.7%), North America (24.4%) and other (3%).

Sector

Pharmaceuticals

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BOIRON

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

31.55 EUR

Average target price

39.6 EUR

Spread / Average Target

+25.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
BOIRON	-21.18%	598M
DONG-E-E-JIAO CO.,LTD.	+13.97%	4.99B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-32.08%	3.61B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.63%	3.1B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.62%	2.64B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-9.82%	2.32B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+38.87%	1.85B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+38.84%	1.43B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-15.47%	1.39B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	1.37B

Alternative Medicine

BOIRON

Equities

BOI

FR0000061129

Pharmaceuticals

Boiron : ACTIVITY IN 2016

Latest news about BOIRON

Chart BOIRON

Company Profile

Income Statement Evolution

Ratings for BOIRON

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Alternative Medicine